The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps ...

The FDA has approved the first blood test for diagnosing Alzheimer’s disease, which could speed the path to treatment for ...

The Food and Drug Administration cleared a new kind of test for Alzheimer’s disease designed to be more accessible and less ...

US regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find ...

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...

The FDA has cleared Fujirebio Diagnostics' Lumipulse blood test, marking the first of its kind for Alzheimer's diagnosis.

(Reuters) -The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's ...

The comments come just a couple months after the company slashed its 2027 sales expectations for the Biogen-partnered ...

AI has the power to cut care delays and manage data overload, but trust gaps among clinicians and patients threaten to slow adoption and impactAmsterdam, the Netherlands ? Royal Philips , a global ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 ...

The drop in GPM is likely due to the increasing proportion of sales from Leqembi, one of Eisai’s products. The company’s guidance for current-year sales of ¥790 billion, which is the same as last year ...